Rapid Development of Human Neutralizing Monoclonal Antibodies for SARS-CoV-2

Antibody

Research Institution

Vanderbilt Vaccine Center

Description

We are rapidly developing human neutralizing monoclonal antibodies for SARS-CoV-2. We need funds or services in kind for manufacture and clinical trials of human monoclonal antibodies. We are less than 6 months from trialing in humans.

Research Team

James Crowe
Director
Vanderbilt Vaccine Center
Robert Carnahan
Associate Director
Vanderbilt Vaccine Center

Project Details

Funding Sources

DARPA, NIH

Project Phases

Planned Time to Trials

< 6 Months

Needs

Hover for more information.
Funding
Partnerships
Expert Advice

Get In Touch

Directly connect with the responsible researchers by sending a message.
Thank you! Your message has been received and will be forwarded to the research team!
Oops! Something went wrong while submitting the form.